TIL Therapies: A Deep Dive in Targets for Cancer IO

This webinar, the third of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind tumor-infiltrating lymphocyte therapies. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.

• Brian R. Gastman, MD – Cleveland Clinic Cancer Center
  
• Stephanie L. Goff, MD, FACS – National Cancer Institute Surgery Branch

Faculty:

• Amod A. Sarnaik, MD - H.Lee Moffitt Cancer Center and Research Institute

Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series here!

Targets for Cancer IO: A Deep Dive Series is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc. (as of 6/6/2022).

#TargetsforCancerImmunotherapyADeepDiveSeminarSeries #NoCEOffered #Industry #Researcher #2022